CFT8634 Phase 1 Dose Escalation Data to be Presented at the Connective Tissue Oncology Society Annual Meeting on November 2, 2023 CFT7455 Monotherapy Phase 1 Dose Escalation Complete in Relapsed/Refractory Multiple Myeloma; Data to be Presented at a Company-Sponsored Event on December 12, 2023 Phase 1 Dose Escalation Continues to Progress for CFT7455 in Combination with Dexamethasone in Relapsed/Refractory Multiple Myeloma and as a Monotherapy in Non-Hodgkin’s Lymphoma WATERTOWN, Mass., Oct.

CFT8634第1阶段剂量递增数据将于2023年11月2日在结缔组织肿瘤学会年会上提交CFT7455单一疗法第1阶段剂量递增在复发/难治性多发性骨髓瘤中完成；将于2023年12月12日在公司赞助的活动中呈现的数据CFT7455联合地塞米松治疗复发/难治性多发性骨髓瘤的第一阶段剂量递增继续进展，并作为非霍奇金淋巴瘤WATERTOWN，Mass。，Oct。

11, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced plans to share data from the Phase 1 dose escalation portions of the ongoing Phase 1/2 trials of CFT7455 and CFT8634.

112023（GLOBE NEWSWIRE）-C4 Therapeutics，Inc。（C4T）（纳斯达克股票代码：CCCC），一家临床阶段生物制药公司，致力于推进靶向蛋白质降解科学，开发新一代小分子药物并改变疾病的治疗方式，今天宣布计划分享CFT7455和CFT8634正在进行的1/2期试验的1期剂量递增部分的数据。

The CFT8634 Phase 1 dose escalation data has been accepted as a poster presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place from November 1 – 4, 2023 in Dublin, Ireland. C4T will host a company-sponsored event on December 12, 2023, to share the CFT7455 dose escalation data in relapsed/refractory multiple myeloma (R/R MM).

CFT8634 1期剂量递增数据已被接受为2023年11月1日至4日在爱尔兰都柏林举行的结缔组织肿瘤学会（CTOS）年会上的海报展示。C4T将于2023年12月12日举办公司赞助的活动，分享复发/难治性多发性骨髓瘤（R/R MM）的CFT7455剂量递增数据。

Upcoming CFT8634 Clinical Data The Phase 1/2 trial is designed to characterize safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and evidence of anti-tumor activity of CFT8634 based on RECIST 1.1 criteria. As of August 29, 2023, 32 patients were enrolled across six dose escalation cohorts using a daily dosing schedule.

即将到来的CFT8634临床数据1/2期试验旨在根据RECIST 1.1标准表征CFT8634的安全性，耐受性，药代动力学（PK），药效学（PD）和抗肿瘤活性证据。截至2023年8月29日，使用每日给药方案在六个剂量递增队列中招募了32名患者。

CTOS Presentation Details Title: Initial results from a Phase 1 study of CFT8634, a novel bifunctional degradation activating compound (BiDAC) degrader of BRD9, in synovial sarcoma and SMARCB1-nul.

CTOS介绍细节标题：来自CFT8634的第一阶段研究的初步结果，CFT8634是一种新型双功能降解激活化合物（BiDAC）降解BRD9，在滑膜肉瘤和SMARCB1 nul中。